Precigen, Inc.
PGENNASDAQ
Healthcare
Biotechnology
$3.94
+0.01(0.1%)
52W $1.17 – $5.21
Quick:
SCHEDULE 13D/A
Mar 31, 2026 (6 days ago)SCHEDULE 13D/A (Amendment)
SEC filing disclosure
Filing details and context
10-K
Mar 25, 2026 (1 weeks ago)Annual Report
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures
8-K
Mar 25, 2026 (1 weeks ago)Current Report
Material event disclosure
Event materiality and market reaction
SCHEDULE 13G/A
Feb 13, 2026 (1 months ago)Beneficial Ownership (Amendment)
Large shareholder position disclosure
Ownership threshold, passive vs active
SCHEDULE 13G
Jan 23, 2026 (2 months ago)Beneficial Ownership
Large shareholder position disclosure
Ownership threshold, passive vs active
SCHEDULE 13D/A
Nov 21, 2025 (4 months ago)SCHEDULE 13D/A (Amendment)
SEC filing disclosure
Filing details and context
8-K
Nov 13, 2025 (4 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Nov 13, 2025 (4 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
SCHEDULE 13G/A
Oct 30, 2025 (5 months ago)Beneficial Ownership (Amendment)
Large shareholder position disclosure
Ownership threshold, passive vs active
SCHEDULE 13G
Sep 23, 2025 (6 months ago)Beneficial Ownership
Large shareholder position disclosure
Ownership threshold, passive vs active
SCHEDULE 13D/A
Sep 19, 2025 (6 months ago)SCHEDULE 13D/A (Amendment)
SEC filing disclosure
Filing details and context
8-K
Sep 17, 2025 (6 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Sep 3, 2025 (7 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Aug 18, 2025 (7 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Aug 18, 2025 (7 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Aug 12, 2025 (7 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
Jun 30, 2025 (9 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
May 14, 2025 (10 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
May 14, 2025 (10 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
10-K/A
Apr 28, 2025 (11 months ago)Annual Report (Amendment)
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures